首页|治疗疼痛的抗体药物的临床进展

治疗疼痛的抗体药物的临床进展

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
疼痛是一种与实际或潜在组织损伤相关的,或类似的不愉快的感觉和情感体验,它极大地影响着人们的生活质量.临床应用发现,传统的非甾体、阿片类小分子镇痛药存在不同程度的不良反应甚至诱发成瘾性,因此,开发新型无成瘾性的镇痛药物具有迫切的临床需求.作为镇痛药物开发的新方向,抗体类药物可以特异性地阻断疼痛信号传导、降低神经敏化,且无阿片类药物的成瘾性问题,具有更好的安全性.对目前在疼痛治疗领域的抗体类药物的最新应用和临床进展进行总结,主要包括靶向神经生长因子、原肌球蛋白受体激酶A、降钙素基因相关肽、降钙素基因相关肱受体、垂体腺苷酸环化酶激活肽38、垂体腺苷酸环化酶激活肽受体1等的单克隆抗体,可用于治疗类风湿性关节炎、骨关节炎、慢性腰痛、偏头痛等疾病.以期为抗体药物在疼痛治疗中的进一步研发和应用提供思路和指导.
Clinical Progress of Antibody Drugs for Pain Treatment
Pain,which is an unpleasant sensory and emotional experience associated with actual or potential,or similar,tissue damage,greatly affects people's quality of life.Clinical data have revealed that traditional non-steroidal and opioid small-molecule analgesics have varying degrees of adverse effects and even induce addiction,so there is an urgent clinical need to develop novel non-addictive analgesic drugs.As a new direction for analgesic drug development,antibody-based drugs can specifiically block pain signaling,reduce nerve sensitization,and have better safety without the problem of addiction to opioids.This review summarizes the latest applications and clinical progress of antibody-based drugs in the field of pain management,mainly including monoclonal antibodies targeting nerve growth factor(NGF),tropomyosin receptor kinase A(TrkA),calcitonin gene-related peptide(CGRP),calcitonin gene-related peptide receptor(CGRPR),pituitary adenylate cyclase-activating polypeptide 38(PACAP38)and pituitary adenylate cyclase-activating polypeptide 1 receptor(PAC1R),which can be used to treat rheumatoid arthritis,osteoarthritis,chronic low back pain,migraine and other diseases.This review aims to provide some ideas and guidance for further development and application of antibody drugs for pain treatment

painnerve growth factortropomyosin receptor kinase Acalcitonin gene-related peptidecalcitonin gene-related peptide receptorpituitary adenylate cyclase-activating polypeptide 38pituitary adenylate cyclase-activating polypeptide 1 receptor

王永梅、彭凯婷、王琪、王桂凤、王春河

展开 >

中国科学院上海药物研究所,上海 201203

疼痛 神经生长因子 原肌球蛋白受体激酶A 降钙素基因相关肽 降钙素基因相关肽受体 垂体腺苷酸环化酶激活肽38 垂体腺苷酸环化酶激活肽受体1

上海市科技创新行动计划项目国家自然科学基金

21S1190450032370958

2024

10.20053/j.issn1001-5094.2024.01.004

药学进展
中国药科大学

药学进展

影响因子：0.624
ISSN：1001-5094
年,卷(期)：2024.48(1)
  • 72